All In Biotech

NDA 020327 · Bracco

Isovue-370

Iopamidol · Injection · Radiographic Contrast Agent

Last checked: Nov 20, 2026Latest source record: Jan 13, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1994

Oct 12, 1994

Approved uses

1

Original approval plus efficacy supplements

Registered trials

37

2 Phase 3, 1 recruiting

FAERS reports

2,951

2,159 serious, 261 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISKS ASSOCIATED WITH INTRATHECAL ADMINISTRATION Intrathecal administration of ISOVUE, even if inadvertent, can cause death, convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, and brain edema [see Warnings and Precautions ( 5.1 )]. ISOVUE Imaging Bulk Package is for intra-arterial or intravenous use only [see Dosage and Administration ( 2.2 , 2.3 , 2.4 )] . WARNING: RISKS ASSOCIATED WITH INTRATHECAL ADMINISTRATION Intrathecal administration of ISOVUE, even if inadvertent, can cause death, convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, and brain edema. ISOVUE Imaging Bulk Package is for intra-arterial or intravenous use only. ( 5.1 )

What it is approved for

From the label in effect Feb 14, 2026.

ISOVUE is a radiographic contrast agent indicated for: Intra-arterial Procedures † ( 1.1 ) Cerebral arteriography in adults Peripheral arteriography in adults Selective visceral arteriography and aortography in adults Coronary arteriography and cardiac ventriculography in adults Angiocardiography in pediatric patients Intravenous Procedures † ( 1.2 ) Excretory urography in adults and pediatric patients Computed tomography (CT) of head and body in adults and pediatric patients Peripheral venography in adults † Specific concentrations are recommended for each type of imaging procedure. ( 2.2 , 2.3 , 2.4 ) 1.1 Intra-arterial Procedures † ISOVUE is indicated for: Cerebral arteriography in adults Peripheral arteriography in adults Selective visceral arteriography and aortography in adults Coronary arteriography and cardiac ventriculography in adults Angiocardiography in pediatric patients 1.2 Intravenous Procedures † ISOVUE is indicated for: Excretory urography in adults and pediatric patients Computerized tomography (CT) of the head and body in adults and pediatric patients Peripheral venography in adults † Specific concentrations of ISOVUE are recommended for each type of imaging procedure [see Dosage and Administration ( 2.2 , 2.3 , 2.4 )].

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 12, 1994 Original approval · Type 5 - New Formulation or New Manufacturer
4 products under this application
  • ISOVUE-370 · IOPAMIDOL 76% · INJECTABLE, INJECTION · Prescription
  • ISOVUE-250 · IOPAMIDOL 51% · INJECTABLE, INJECTION · Discontinued
  • ISOVUE-300 · IOPAMIDOL 61% · INJECTABLE, INJECTION · Prescription
  • ISOVUE-200 · IOPAMIDOL 41% · INJECTABLE, INJECTION · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Iopamidol" as an intervention, any sponsor and status, largest first.

All 37 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea191
  • urticaria191
  • anaphylactic reaction186
  • pruritus174
  • nausea164
  • contrast media reaction144
  • no adverse event140
  • vomiting122
  • acute kidney injury115
  • hypersensitivity110
  • off label use93
  • dizziness89

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200432
200536
20067
200720
200825
200923
201059
201182
201278
2013129
2014146
2015149
2016160
2017203
2018207
2019282
2020172
2021193
2022186
2023140
2024169
2025185
2026268

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 264 on PubMed

Sponsor: Bracco · Also marketed as Isovue-250, Isovue-300, Isovue-200

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.